This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Pamela A. Sample, PhD; Daniel J. Plummer, PhD; Arthur J. Mueller, MD; Kim I. Matsubara; Alfredo Sadun, MD, PhD; Igor Grant, MD; William R. Freeman, MD

Arch Ophthalmol. 1999;117:755-760.

Objective  To determine the topographic pattern of visual field loss, if any, and its relationship to the stage of disease in human immunodeficiency virus–positive patients without infectious retinopathy.

Methods  A total of 151 eyes from 81 alert and cooperative patients with human immunodeficiency virus were evaluated with visual field testing. Results were analyzed relative to the associated underlying nerve fiber layer patterns associated with retinal ganglion cell axons as they traverse the retina to the optic nerve. The stage of visual field loss was analyzed relative to the length of survival using Kaplan-Meier survival analysis.

Results  No correlation of CD4 cell count with visual field mean defect (r²=0.23) or corrected pattern standard deviation (r²=0.00) was found. A pattern of visual field loss, consistent with sparing of the papillomacular bundles and associated with damage primarily to the inferior retina external to the posterior pole, was found. Survival analysis indicated a significant difference in time of survival between individuals with normal visual fields and those with a diffuse visual field loss, with a trend to less survival with increasing field loss severity.

Conclusions  These results are consistent with disease at the level of the optic nerve. The relationship of stage of visual field loss to survival has important implications for early detection of field loss and appropriate therapeutic intervention to maintain function and quality of life.

From the Department of Ophthalmology (Drs Sample, Plummer, Mueller, and Freeman and Ms Matsubara) and HIV Neurobehavioral Research Center (Dr Grant), University of California, San Diego, La Jolla; and Doheny Eye Institute (Dr Sadun), University of Southern California, Los Angeles. The authors have neither financial interest in nor received any payment associated with any device, drug, or instrument mentioned in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 1999;117(6):852-853.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hemorheologic Abnormalities Associated with HIV Infection: In Vivo Assessment of Retinal Microvascular Blood Flow.
Dadgostar et al.
IOVS 2006;47:3933-3938.
ABSTRACT | FULL TEXT  

Neuro-ophthalmological disorders in HIV infected subjects with neurological manifestations
Mwanza et al.
Br. J. Ophthalmol. 2004;88:1455-1459.
ABSTRACT | FULL TEXT  

Induction of Cystine-Glutamate Transporter xc- by Human Immunodeficiency Virus Type 1 Transactivator Protein Tat in Retinal Pigment Epithelium
Bridges et al.
IOVS 2004;45:2906-2914.
ABSTRACT | FULL TEXT